Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned.

10 Apr 2014

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.

9 Apr 2014

Penn Medicine to host symposium on regenerative medicine

The University of Pennsylvania's Institute for Regenerative Medicine will host a symposium on Friday, April 11, 2014 to detail the progress researchers are making toward reprogramming human cells to treat a variety of diseases.

9 Apr 2014

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

A $1.92 million grant from the National Institutes of Health (NIH) was awarded to a research team that focuses on new approaches for treatment of relapsed pediatric acute myelogenous leukemia (rAML), led by Yang Liu, PhD, Bothworth Chair and Director of the Center for Cancer and Immunology Research (CCIR) at Children's Research Institute of Children's National Health System, and Reuven Schore, MD, member of CCIR and attending physician in the Leukemia & Lymphoma Program of the Division of Oncology of the Center for Cancer and Blood Disorders.

9 Apr 2014

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

9 Apr 2014

Abnormal levels of lipid molecules can trigger autism during prenatal brain development

In a groundbreaking York University study, researchers have found that abnormal levels of lipid molecules in the brain can affect the interaction between two key neural pathways in early prenatal brain development, which can trigger autism.

9 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

Novartis Institute researcher receives second annual Andrew Carnegie Prize in Mind and Brain Sciences

Carnegie Mellon University will award the second annual Andrew Carnegie Prize in Mind and Brain Sciences to Ricardo Dolmetsch, global head of neuroscience at the Novartis Institute for Biomedical Research.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Compounds from plant confer protective effects against breast cancer, say researchers

Compounds derived from plant-based sources - including garlic, broccoli and medicine plants - confer protective effects against breast cancer, explain researchers at the University of Pittsburgh Cancer Institute (UPCI), partner with the UPMC CancerCenter.

7 Apr 2014

UCL scientists find new way to artificially control paralyzed muscles using light

A new way to artificially control muscles using light, with the potential to restore function to muscles paralysed by conditions such as motor neuron disease and spinal cord injury, has been developed by scientists at UCL and King's College London.

7 Apr 2014

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.

7 Apr 2014

Researcher pinpoints error in protein formation that could be root of amyotrophic lateral sclerosis

By studying nerve cells that originated in patients with a severe neurological disease, a University of Wisconsin-Madison researcher has pinpointed an error in protein formation that could be the root of amyotrophic lateral sclerosis.

4 Apr 2014

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)-Lou Gehrig's disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients.

4 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.

3 Apr 2014

Researchers investigate how gene regulation affects evolution and development

Johannes Gutenberg University Mainz (JGU) has received EUR 900,000 for three years to investigate, jointly with the Institute of Molecular Biology (IMB), how gene regulation affects evolution and development.

3 Apr 2014

Vestiage completes R&D for two new products

Vestiage™, Inc., the emerging leader in healthy aging, announced today that it has completed R&D for two new products that it intends to launch in upcoming quarters.

2 Apr 2014

Human motor neurons can be quickly generated from stem cells, say researchers

Researchers report they can generate human motor neurons from stem cells much more quickly and efficiently than previous methods allowed. The finding, described in Nature Communications, will aid efforts to model human motor neuron development, and to understand and treat spinal cord injuries and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).

2 Apr 2014

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.

2 Apr 2014

Stem Cells News and Research

Further Reading

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Penn Medicine to host symposium on regenerative medicine

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

Researchers identify experimental drugs to block treatment-resistant leukemia

Abnormal levels of lipid molecules can trigger autism during prenatal brain development

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Novartis Institute researcher receives second annual Andrew Carnegie Prize in Mind and Brain Sciences

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Compounds from plant confer protective effects against breast cancer, say researchers

UCL scientists find new way to artificially control paralyzed muscles using light

Blood sample could diagnose many types of solid cancers

Researcher pinpoints error in protein formation that could be root of amyotrophic lateral sclerosis

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

Researchers investigate how gene regulation affects evolution and development

Vestiage completes R&D for two new products

Human motor neurons can be quickly generated from stem cells, say researchers

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

eBook: Integrated solutions for mesenchymal stem cell research and culture eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo